Close Menu

stock price

Buoyed by a string of positive news, the San Diego firm's stock was up 22 percent in Friday afternoon trading and 80 percent from last week.

Some core labs are expecting long waitlists in 2021 as PacBio's HiFi reads draw interest from researchers looking to put together whole genomes.

Growth was driven by demand in its life science segment, particularly for COVID-19-related products, while the diagnostics segment saw uneven improvement.

Despite the havoc wreaked by the COVID-19 pandemic on the economy, several companies in the index saw their shares rise by triple-digit percentages last year.

The index outperformed the Dow Jones, the Nasdaq, and the Nasdaq Biotechnology Index in December.

The investment bank said that while Twist's biopharma and DNA-based data storage businesses offer upside, the timelines for generating revenues are unclear.

Although the total number of deals went down in 2020, those deals were worth more compared to 2019 — four of the top five had billion-dollar price tags.

A recently published preprint study demonstrated the superiority of the company's optical mapping technology for detecting large structural variations in de novo sequencing data.

Originally, the company had said it was planning to offer $250 million worth of shares in the offering, which is expected to close Dec. 7.

Included in the offering — Twist Bioscience's third this year — are 75,000 shares of common stock offered by certain selling shareholders.

Pages

The Wall Street Journal reports on gaps in COVID-19 testing affecting less affluent urban areas and rural locations.

According to NBC News, new SARS-CoV-2 variants are making it harder for researchers to model the course of the pandemic.

The New York Times reports that experts say President Joe Biden's goal of vaccinating 1 million people a day in the US in the next 100 days is too low a bar.

In Science this week: single-cell lineage tracing technique applied to study lung cancer metastasis, and more.